Practice Matters

Role of the Advanced Practice Provider in Clinical Trials: Contributions to the Management of Patients Receiving Inotuzumab Ozogamicin

Mary Alma Welch,(1) PA-C, Joanne C. Ryan,(2) PhD, RN, and Ilene Ann Galinsky,(3) BSN, MSN, ANP-C

(1)MD Anderson Cancer Center, Houston, Texas; (2)Pfizer Inc, New York, New York; (3)Dana Farber Cancer Institute, Boston, Massachusetts

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Mary Alma Welch, PA-C, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: mawelch@mdanderson.org


J Adv Pract Oncol 2017;8:631–636 | https://doi.org/10.6004/jadpro.2017.8.6.6 | © 2017 Harborside Press®


  



For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me